CD40L-Binding MSC Engineering for Targeted Immunosuppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing immunotherapeutic agents, such as antibody drugs and cell therapeutic agents based on differentiated immune cells or mesenchymal stem cells, have limited efficacy and are costly with unclear mechanisms of action, and there is a need for more effective treatments for immune-related diseases like autoimmune and inflammatory diseases.

Innovation Solution

Genetically modified cells, particularly mesenchymal stromal cells (MSCs), are developed to express a CD40L binding agent, such as a stefin A protein variant, which enhances immunomodulatory activity and reduces immune rejection, using a lentiviral vector to introduce a nucleic acid encoding the CD40L binding agent.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibody drugs against cytokines or cell surface molecules are used, then immune response can be targeted, but efficacy is insufficient and side effects occur

Engineering Contradiction:

ImproveefficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses CD40L-binding proteins (such as stefin A variants) as intermediary molecules that mediate immune modulation by binding to CD40L on activated T cells, thereby controlling immune responses more precisely than direct antibody blockade, reducing off-target effects while maintaining efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the CD40L-binding protein through genetic engineering to create variants with optimized binding affinity and specificity, changing the parameters of the binding agent to achieve better efficacy and reduced side effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If cell therapeutic agents based on differentiated immune cells or mesenchymal stem cells are used, then immune homeostasis can be regulated, but cost is high and mechanism of action is unclear

Engineering Contradiction:

Improvetherapeutic effectVSAvoidcost and mechanism complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the specific functional component (CD40L-binding protein) from complex cell therapies, creating a defined molecular agent that can be produced consistently without requiring complex cell culture systems or autologous cell processing, thereby reducing cost and clarifying mechanism

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs recombinant CD40L-binding proteins that can be produced through standardized biopharmaceutical manufacturing processes, replacing expensive and complex cell-based therapies with more cost-effective molecular agents that can be scaled production

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If mesenchymal stem cells are used for treatment, then immune modulation is achieved, but therapeutic effect is low relative to cost

Engineering Contradiction:

Improveimmunomodulatory activityVSAvoidtherapeutic effect per unit cost

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent enhances the immunomodulatory activity per cell by introducing the CD40L-binding protein gene into mesenchymal stem cells, transforming them from low-activity cells to high-activity protein-secreting cells, thereby significantly improving therapeutic effect relative to cost

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The genetically modified MSCs exhibit superior therapeutic effects on immune-related diseases by modulating immune responses and reducing immune rejection, demonstrating enhanced immunomodulatory activity and stability across multiple passages.

Implementation Method 1

using a lentiviral vector to introduce a nucleic acid encoding the CD40L binding agent

Methodology Applied

Scientific EffectViral transduction:

Implementation Method 2

a nucleic acid encoding a CD40l binding agent (e.g., a stefin A protein variant that specifically binds to CD40L)

Methodology Applied

Scientific EffectProtein binding:

Data Source

PatentUS20260022160A1Genetically modified cells comprising a nucleic acid encoding a CD40l binding agent and uses thereof

Publication Date: 2026.01.22 AFFYXELL THERAPEUTICS CO LTD

AI summary

Disclosed are a genetically modified cell in which a nucleic acid encoding a CD40L binding agent (e.g., a stefin A protein variant specifically binding to CD40L or a fusion protein including the same) is introduced into a host cell and uses thereof. Provided are genetically modified cells expressing a CD40L binding agent enabling secretion thereof, expression thereof on a cell membrane, and/or intracellular localization thereof, and are thereby capable of reducing or inhibiting the activity of CD40L. Provided genetically modified cells may inhibit T-cell activity and B-cell activity and exhibit an immunosuppressive effect, and may be thus useful for the prevention or treatment of immune diseases such as autoimmune diseases or inflammatory diseases.